[HTML][HTML] NF-κB signaling and inflammation—Drug repurposing to treat inflammatory disorders?
A Roberti, LE Chaffey, DR Greaves - Biology, 2022 - mdpi.com
Simple Summary Since its first description 35 years ago, the transcription factor NF-κB
(nuclear factor κ-light-chain-enhancer of activated B cells) has been shown to be a key …
(nuclear factor κ-light-chain-enhancer of activated B cells) has been shown to be a key …
Causal effects of inflammatory protein biomarkers on inflammatory diseases
WE Ek, T Karlsson, J Höglund, M Rask-Andersen… - Science …, 2021 - science.org
Many circulating proteins are associated with the presence or severity of disease. However,
whether these protein biomarkers are causal for disease development is usually unknown …
whether these protein biomarkers are causal for disease development is usually unknown …
A State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD
KO Chudy-Onwugaje, KE Christian… - Inflammatory bowel …, 2019 - academic.oup.com
Over the last 2 decades, novel therapies targeting several immune pathways have been
developed for the treatment of patients with inflammatory bowel disease (IBD). Although anti …
developed for the treatment of patients with inflammatory bowel disease (IBD). Although anti …
IL-23-induced macrophage polarization and its pathological roles in mice with imiquimod-induced psoriasis
Macrophages acquire distinct phenotypes during tissue stress and inflammatory responses.
Macrophages are roughly categorized into two different subsets named inflammatory M1 …
Macrophages are roughly categorized into two different subsets named inflammatory M1 …
Cytokines and transcription factors in the differentiation of CD4+ T helper cell subsets and induction of tissue inflammation and autoimmunity
M Pawlak, AW Ho, VK Kuchroo - Current opinion in immunology, 2020 - Elsevier
CD4+ T helper (Th) cells are critical in homeostasis and host defense but are also central to
the development of various autoimmune diseases if they become dysregulated. Specifically …
the development of various autoimmune diseases if they become dysregulated. Specifically …
[HTML][HTML] Phage-assisted continuous evolution of proteases with altered substrate specificity
Here we perform phage-assisted continuous evolution (PACE) of TEV protease, which
canonically cleaves ENLYFQS, to cleave a very different target sequence, HPLVGHM, that is …
canonically cleaves ENLYFQS, to cleave a very different target sequence, HPLVGHM, that is …
Psoriasis: recent progress in molecular‐targeted therapies
M Honma, K Hayashi - The Journal of Dermatology, 2021 - Wiley Online Library
Psoriasis is a multifactorial recalcitrant inflammatory skin disease characterized by
bothersome scaly reddish plaques especially on frequently chafed body parts, such as the …
bothersome scaly reddish plaques especially on frequently chafed body parts, such as the …
The action of TH17 cells on blood brain barrier in multiple sclerosis and experimental autoimmune encephalomyelitis
Th17 cells, known as a highly pro-inflammatory subtype of Th cells, are involved very early
in numerous aspects of multiple sclerosis (MS) and experimental autoimmune …
in numerous aspects of multiple sclerosis (MS) and experimental autoimmune …
[HTML][HTML] Large-scale genome-wide enrichment analyses identify new trait-associated genes and pathways across 31 human phenotypes
X Zhu, M Stephens - Nature communications, 2018 - nature.com
Genome-wide association studies (GWAS) aim to identify genetic factors associated with
phenotypes. Standard analyses test variants for associations individually. However, variant …
phenotypes. Standard analyses test variants for associations individually. However, variant …
Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III …
CT Ritchlin, PS Helliwell, WH Boehncke, ER Soriano… - RMD open, 2021 - rmdopen.bmj.com
Objective Evaluation of the efficacy and safety of guselkumab, a human monoclonal
antibody targeting the interleukin-23p19 subunit, in patients with psoriatic arthritis (PsA) …
antibody targeting the interleukin-23p19 subunit, in patients with psoriatic arthritis (PsA) …